Closed · HR001121S0038 · CFDA 12.910 · Discretionary

Reimagining Protein Manufacturing (RPM)

Federal grant opportunity posted by DARPA - Biological Technologies Office, cataloged on Grants.gov.

Varies
Award range
Closed
Status
November 16, 2021
Close date
-
Expected awards

The verdict

Reimagining Protein Manufacturing (RPM) is a closed discretionary listing from DARPA - Biological Technologies Office that offered Varies by applicant. Future funding cycles may be published under the same CFDA number.

Varies
award range
Closed
application status
12.910
CFDA program

Opportunity snapshot. This Grants.gov announcement - Reimagining Protein Manufacturing (RPM) - is cataloged under number HR001121S0038 and tied to CFDA assistance listing 12.910, posted by DARPA - Biological Technologies Office. Grants.gov currently shows the opportunity as closed, first posted on August 23, 2021. The funding category is Discretionary, delivered as a procurement contract.

Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.

Deadline and action path. This opportunity closed on November 16, 2021. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.

Award Range

Varies by applicant

Close Date

November 16, 2021

See Full Announcement for details.

Posted

August 23, 2021

Instrument

Procurement Contract

Description

The Reimagining Protein Manufacturing (RPM) program aims to ensure timely DoD access to critical medical countermeasures (MCMs) by establishing the foundational technologies needed for fully distributed, on-demand manufacturing of protein-based MCMs and associated raw materials. To achieve this goal, RPM will develop technologies to enable immediate synthesis (lead time approximately 24 hours) of bioactive protein MCMs and raw material production enzymes at a yield corresponding to > 500 doses per week. This technology will allow the DoD to rapidly secure access to both therapeutic proteins and enzymes needed for nucleic acid-based MCM synthesis, and reduce reliance on complex supply chains.

Eligibility

Grants.gov lists this opportunity under eligibility category code 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

BAA Coordinator RPM@darpa.mil

Key Dates

Posted August 23, 2021
Close Date November 16, 2021
Archive Date December 16, 2021
Last Updated August 23, 2021

Frequently Asked Questions

What is this grant opportunity?
This is a federal funding opportunity titled "Reimagining Protein Manufacturing (RPM)", offered by DARPA - Biological Technologies Office. It is associated with CFDA program 12.910. The Reimagining Protein Manufacturing (RPM) program aims to ensure timely DoD access to critical medical countermeasures (MCMs) by establishing the foundational technologies needed for fully distribut...
Is this opportunity still open?
No, this opportunity is closed. It closed on November 16, 2021. Check the parent program page for future funding cycles.
How much funding is available?
The award range for this opportunity is Varies by applicant.
How do I apply?
Applications for federal grant opportunities are typically submitted through Grants.gov. Visit the official listing at grants.gov for application instructions, required documents, and submission deadlines.

More from DARPA - Biological Technologies Office

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants